Brooklyn ImmunoTherapeutics, Inc.: directors' dealings · United States · SEC (Form 4)

About Brooklyn ImmunoTherapeutics, Inc.

Brooklyn ImmunoTherapeutics, Inc. was a United States-based biopharmaceutical company historically listed on the Nasdaq market under the ticker BTX, before the company changed its name to Eterna Therapeutics Inc. in 2022. For investors, this is an important point of reference: much of the public information tied to BTX belongs to the company’s earlier corporate identity, and the subsequent name change can create confusion when reviewing SEC filings, corporate announcements, and market history. The company’s profile was that of an early-stage biotech rather than a commercial-stage pharmaceutical business. Brooklyn ImmunoTherapeutics was built around immunology-driven innovation, with a strategic focus on cytokine-based therapies, gene editing, cellular therapy, and, later, an mRNA-enabled cell reprogramming platform. The company described itself in SEC materials as a platform company pursuing next-generation engineered cellular, gene-editing, and cytokine products aimed at high-unmet-need indications such as cancer, blood disorders, and monogenic diseases. In practical terms, that means the business was centered on research and development, preclinical work, and clinical development optionality, rather than recurring product sales. The company’s history shows a strategic transition. It initially emphasized cytokine immunotherapy, including its IRX-2 program, and then moved toward a broader platform strategy. Public filings and company communications indicate that its newer development model relied in part on licensed mRNA technology from Factor Bioscience, which was positioned as a foundation for internal pipeline programs. This kind of strategy is common among micro- and small-cap biotechnology firms that seek to create a pipeline of multiple candidates from a shared technology base. Competitive positioning was challenging and highly speculative. Brooklyn operated in a crowded field populated by much larger pharmaceutical companies, platform biotech peers, and well-funded private developers. Its potential competitive edge came from scientific flexibility and the possibility of generating multiple therapeutic candidates from one technology stack. The trade-off was substantial execution risk: clinical risk, regulatory risk, capital-market dependence, and the possibility of dilution are all meaningful issues in this segment. As a U.S. issuer, the company’s market context was the Nasdaq in the United States, with operations and investor visibility largely anchored in the U.S. biotech ecosystem. Publicly discussed product lines included cytokine therapies, engineered cell therapies, and gene-editing programs. A major recent corporate milestone was the 2022 name change from Brooklyn ImmunoTherapeutics to Eterna Therapeutics, which investors should keep in mind when tracing insider transactions, SEC Form 4 activity, and historical filings tied to BTX.